Author

Y. Horisawa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Takaori-Kondo· 3 shared K. Shirakawa· 3 shared Y. Kazuma· 3 shared A. Saito· 2 shared E. P. Butlertanaka· 2 shared I. Kimura· 2 shared J. Wu· 2 shared K. Sato· 2 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. Takaori-Kondo

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MicrobiologybioRxivJul 28, 2021

SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance

I. Kimura, Y. Kosugi, J. Wu…·K. Sato

The paper investigates the SARS-CoV-2 Lambda variant, finding it more infectious due to specific mutations and better immune evasion, contributing to its spread in South America.

DOI 10.1016/j.celrep.2021.110218

humanexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivJun 17, 2021

SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity

A. Saito, T. Irie, R. Suzuki…·K. Sato

This study shows the P681R mutation in the SARS-CoV-2 spike protein enhances fusogenicity and pathogenicity in the Delta variant compared to the prototypic virus.

DOI 10.1038/s41586-021-04266-9

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivSep 24, 2019

APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression

H. Yamazaki, K. Shirakawa, T. Matsumoto…·A. Takaori-Kondo

The paper develops APOBEC3B reporter myeloma cell lines to study DNA damage response pathways that regulate APOBEC3B expression, finding that conventional therapies increase its expression while targeted drugs do not.

DOI 10.1371/journal.pone.0223463

humanproteomics

𝕏 PostBluesky